Retex Pharmaceuticals Inc. has patented vasopressin V2 receptor antagonists potentially useful for the treatment of hyponatremia, cardiovascular disorders, autosomal dominant and autosomal recessive polycystic kidney.
Merck Sharp & Dohme LLC (MSD) has reported compounds acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors designed for use in the treatment of cancer.
Biofront Therapeutics (Beijing) Co. Ltd. has prepared and tested cathepsin L (CTSL) inhibitors potentially useful for the treatment of acute respiratory distress syndrome (ARDS), cancer, diabetes, liver injury, viral infections and bone, inflammatory and renal disorders, among others.
Gan & Lee Pharmaceuticals Co. Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)- and/or SMARCA4-targeting moiety.
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein τ (PHF-τ; MAPT) aggregation inhibitors.
Waverley Pharma Inc. has discovered substituted (3-hydroquinazolin-4-one) derivatives acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors and thus potentially useful for the treatment of cancer.
Shanghai Meiyue Biotech Development Co. Ltd. has patented heterocyclic derivatives acting as KIT (c-KIT) inhibitors. They are reported to be useful for the treatment of autoimmune, metabolic disease, cancer, diabetes, fibrosis, urticaria, inflammatory and respiratory disorders, among others.
RSS